Sepsis is a condition wherein the body’s response to infection triggers an inflammation reaction throughout the body. The immune system releases inflammatory chemicals into the bloodstream to clear out pathogens from the body, but instead these chemicals cause a cascade of reactions that result in organ damage and may be fatal. A few of the symptoms of sepsis include low blood pressure, mental confusion, fever, an increased heart rate, and difficulty breathing. Sepsis may be caused by infectious agents such as bacteria, viruses, and fungi. Several factors that increase the risk of sepsis include old age, diabetes, liver disease, the use of antibiotics, and the use of invasive medical devices such as catheters.
Market Dynamics
Market players are conducting clinical trials for developing more efficient diagnostic systems for sepsis, which could contribute to the growth of the market over the forecast period. For instance, in February 2020, Inflammatix, Inc., a California, U.S. based diagnostics company, initiated a clinical trial study for their product HostDx Sepsis with 1500 participants, which is expected to be completed by November 2021. This clinical study investigates the performance of the HostDx Sepsis diagnostic test in the diagnosis and prognosis of patients with suspected sepsis.
Market players are involved in expanding their presence globally by entering into collaboration with other companies in order to enhance distribution, which is expected to drive the growth of the global sepsis diagnostics market. For instance, in May 2020, BARDA (Biomedical Advanced Research and Development Authority) and Beckman Coulter Inc., a California, U.S. based biomedical testing solutions provider, entered into a strategic collaboration for the development of a diagnostic algorithm for early detection of sepsis in COVID-19 patients.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook